Avid Bioservices, Inc. announced that the company is expanding its CDMO service offering into the rapidly growing cell and gene therapy market. Additionally, Avid has appointed Drew Brennan, an experienced CDMO business development executive as general manager of viral vector technologies to lead its expansion into the cell and gene therapy market. As newly appointed general manager of viral vector technologies, Mr. Brennan will be responsible for overseeing all business activities related to Avid’s expansion into the cell and gene therapy market. He most recently spent more than a decade in senior sales and operations positions at Novasep, a leading provider of equipment and services in the fields of both small molecule and biologics production and purification for the life science and chemical industries. His tenure at Novasep culminated in his serving as general manager for Novasep’s U.S. subsidiary, with responsibility for all products including viral vector CDMO services.